Rally in Chinese healthcare signals a structural shift, not a fleeting rebound
Three factors are driving the industry’s market outperformance in Asia
CHINESE healthcare is leading Asia’s capital markets in 2025, transforming from a domestic growth story into a global force in innovation and investment. This rally has been anchored by blockbuster initial public offerings (IPOs) in Hong Kong, including Hengrui Pharma’s US$1.5 billion listing and DualityBio’s oversubscribed debut, which together highlight the depth of institutional demand and the sector’s growing role as a cornerstone of regional equity markets.
Both the Hang Seng Biotech and Healthcare Index have soared this year, rising 83 per cent and 74 per cent year-to-date, respectively – dwarfing the broader Hang Seng Index’s 27 per cent gain.
More than a cyclical rebound, this momentum signals the start of a structural shift. The healthcare sector is emerging as the frontrunner in driving innovation, attracting investment, and shaping market leadership, not just in Asia but globally.
Share with us your feedback on BT's products and services
